Hypertension and COVID-19: Potential use of beta-blockers and a call for randomized evidence

Hypertension is one of the most common morbidities in COVID-19. Previous studies demonstrated that hypertension increases composite poor outcomes in patients with COVID-19. Beta-blockers is widely used as one of the most common antihypertensive agents. Beta-blockers may hold potential benefits in CO...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsagaff, Mochamad Yusuf, Mulia, Eka Prasetya Budi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Opinion Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550882/
https://www.ncbi.nlm.nih.gov/pubmed/34717930
http://dx.doi.org/10.1016/j.ihj.2021.10.011
Descripción
Sumario:Hypertension is one of the most common morbidities in COVID-19. Previous studies demonstrated that hypertension increases composite poor outcomes in patients with COVID-19. Beta-blockers is widely used as one of the most common antihypertensive agents. Beta-blockers may hold potential benefits in COVID-19 treatment, with current evidence of the potential mechanism of beta-blockers remains scarce. However, several mechanisms were suggested, including decreasing RAAS pathway activity and lowering the ACE2 levels, reducing cytokine storms, and may be beneficial in reducing mortality in ARDS related COVID-19. Further large-scale randomized clinical trials should be conducted before a definite recommendation can be drawn.

Ejemplares similares